5 results match your criteria: "Hospital Universitario Fundacion Favaloro Buenos Aires[Affiliation]"
Arch Peru Cardiol Cir Cardiovasc
March 2024
Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina. Instituto Cardiovascular de Buenos Aires Buenos Aires Argentina.
Objectives: To identify predictors of coronary artery bypass graft surgery (CABG) requirement as a revascularization method in in real-world non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients.
Materials And Methods: . An individual pre-specified analysis of patients with NSTE-ACS was performed from two prospective Argentine registries between 2017 and 2022.
Arch Peru Cardiol Cir Cardiovasc
September 2023
Instituto Cardiovascular de Buenos Aires. Buenos Aires, Argentina. Instituto Cardiovascular de Buenos Aires Buenos Aires Argentina.
Objectives: To evaluate the rate of use of antiplatelet pretreatment in patients with non-ST elevated acute coronary syndrome (NSTEACS) and its association with adverse events in two Argentine registries.
Materials And Methods: We retrospectively analyzed two Argentine acute coronary syndrome (ACS) registries from 2017 and 2022. We explored the incidence of pretreatment and the drug used.
Treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in Latin America differs between countries, with regard to disease etiology, health insurance coverage, and drug availability. A group of experts from Latin America, met to share regional experiences and propose possible lines of collaboration. The available evidence, regional clinical practice data, and the global context of the proceedings of the 6th World Symposium on Pulmonary Hypertension, held in Nice, France, in February 2018, were analyzed.
View Article and Find Full Text PDFCardiovasc Revasc Med
September 2017
Cardiology and Cardiovascular Surgery Institute (ICyCC), Hospital Universitario. Fundación Favaloro. Buenos Aires. Argentina.
Transcatheter aortic valve replacement (TAVR) represents a viable therapeutic option in patients with severe symptomatic aortic valve stenosis. The development of a left ventricular pseudoaneurysm (LVP) represents an infrequent but potentially catastrophic complication after transapical TAVR. In this case report, we present a patient undergoing TAVR through subclavian access which had an LVP and underwent successful percutaneous closure.
View Article and Find Full Text PDF